How to Predict Blood Clot Risk in Cancer Patients?

People with cancer and non-O blood types, such as types A, B, and AB, face an increased risk of developing venous thromboembolism (VTE), or blood clots in the veins, suggests a new study published in Blood Advances.

Scientists have long strived to understand the risk factors for VTE, the leading cause of preventable hospital deaths in the United States.

Pulmonary Embolism and Deep Vein Thrombosis / Venous Thromboembolism
Deep vein thrombosis (DVT) is a condition where blood clots develop usually in the deep veins of the legs. Pulmonary embolism (PE) occurs when these clots break away and block the pulmonary artery.

‘Easily performed blood group typing may serve as another important measure in predicting blood risk among cancer patients.’

Tweet it Now

Existing assessments use factors like tumor or cancer type to detect those at high risk of VTE. Yet, many patients without these diagnoses still develop life-threatening blood clots but go unidentified.

VTE includes deep-vein thrombosis (DVT), a blood clot that typically forms in the deep veins of the leg, and pulmonary embolism (PE), a life-threatening condition that occurs when a blood clot breaks free and becomes lodged in the arteries of the lung.

Cancer and cancer therapies also increase one’s chances of developing blood clots, and while people with severe forms of cancer are more likely to develop VTE, less research exists on the risk among patients with cancers less associated with thrombosis.

Being Tall Increases the Risk for Blood Clots in Veins
Venous thromboembolism risk is high in individuals who are taller when compared to shorter people who are at lower risk of developing the disease.

In the new study, researchers investigated the role of non-O blood types in participants’ likelihood of developing VTE. They collected data from 1,708 adult participants with a new or recurrent cancer diagnosis from the Vienna Cancer and Thrombosis Study (CATS) data set.

Researchers grouped participants first by blood type, then sorted them based on their tumor classification. Patients with pancreatic, gastroesophageal, and brain cancer tumors were considered to have high-risk diagnoses.

Effect of Blood Group Type on COVID-19 Risk and Severity
A new study investigated the impact of ABO and Rh blood groups on COVID-19 susceptibility, prognosis, recovery time, and mortality.

While tumor type can be useful in identifying people more likely to develop VTE, many people with less severe tumors still experience dangerous blood clots and therefore may require additional monitoring and treatment.

“We’ve known tumor type helps determine the baseline risk for VTE. But we continue to see that these risk assessments fail to capture all cancer patients who develop these blood clots,” explained study author Cornelia Englisch, an MD-PhD student at the Medical University of Vienna.

Making Universal Donor O Group Blood From Other Groups
Scientists identify enzymes secreted by human gut bacteria that may be able to help convert A, B and AB group blood to O group blood or universal blood -blood that can be given to persons having any blood group

Their results indicated that patients with non-O blood types were more likely to develop VTE three months after their diagnosis or reoccurrence of cancer.

This association did not appear at the time of diagnosis because cancer therapies increase patients’ likelihood of developing blood clots, making blood type a less significant predictor of VTE during the early stages of treatment.

Those with tumors outside of the high-risk disease category with non-O blood type were more likely to develop blood clots independent of time, showing that exclusively depending on a tumor type to detect VTE risk may cause many patients to fall through the cracks.

While these findings are exploratory and still require additional study. Going forward, researchers also aim to better understand the biological mechanisms underlying these findings. They hope that blood typing can serve as a useful tool in risk assessments for cancer-associated VTE in the future.

Source-Medindia